RE:Reality CheckIt's been forgotten, but the issue (if memory serves since it's been such a long time) with IND-213 was that the principal investigators believed that the cohorts were insufficiently randomized. Hence Bracelet.
I've been in this stock since the busted P3 for head-and-neck. Should have bailed then, but stuck around dollar-cost averaging out of FOMO. (Strangely, investing and following this stock has actually become something of a hobby for me.) From head-and-neck to metastic breast cancer to immunocology and now to pancreatic. I had actually promised myself that I would get out after Bracelet. When they released the Panc results last December (which were legitimately good), I had a sneaking suspicion that management intended for Panc to supersede MBS. Another bait for longs.
I am now in it until the end of the year. Why? Because I actually think that there is some efficacy here. I want to see the OS data for Bracelet and the colerectral results. I do think that if this company had a shorter operating history (say, 5 years) and better management that we would be trading at multiples of the current price.
That said, there are many, many red flags: (1) lack of insider and institutional ownership, (2) inability to execute trials in a timely manner, (3) changing narratives on MOA, (4) changing trial focus. I could go on.